MedPath

Yeshurun Moshe

🇮🇱Israel
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

2 Phases

Phase 2:2
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 3
1 (33.3%)

N-acetyl Cysteine for the Prevention of Oral Mucositis After Autologous Hematopoietic Cell Transplantation.

Phase 3
Conditions
Mucositis
Transplant-Related Disorder
Interventions
First Posted Date
2021-02-16
Last Posted Date
2021-02-16
Lead Sponsor
moshe yeshurun
Target Recruit Count
116
Registration Number
NCT04756622

Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease

Phase 2
Conditions
Acute-graft-versus-host Disease
Interventions
First Posted Date
2015-03-19
Last Posted Date
2015-03-19
Lead Sponsor
moshe yeshurun
Target Recruit Count
10
Registration Number
NCT02392780
Locations
🇮🇱

Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petach Tikva, Israel

Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation

Phase 2
Conditions
Pediatric Patients Undergoing Allogeneic Cord Blood Transplantation.
Interventions
First Posted Date
2013-09-12
Last Posted Date
2015-06-16
Lead Sponsor
moshe yeshurun
Target Recruit Count
20
Registration Number
NCT01940562
Locations
🇮🇱

Hadassah hospital, Jerusalem, Israel

🇮🇱

Schneider Children's Medical Center of Israel, Petah Tikva, Israel

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.